Arcus Biosciences Inc (NYSE:RCUS)
$ 16 0.16 (1.01%) Market Cap: 1.46 Bil Enterprise Value: 456.70 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 75/100

Arcus Biosciences Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 12:30PM GMT
Release Date Price: $17.17
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Good morning. My name is Peter Lawson. Welcome to Barclays Global Healthcare Conference in Miami. I'm really pleased to have with us -- up on the stage with us, Arcus. So we've got management team. We've got Terry Rosen, CEO, Co-Founder; and Jennifer Jarrett, COO.

Questions & Answers

Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

And I guess the first question would be really around -- I guess you've answered this multiple times around ARC-7, kind of underperformance, kind of how you think about the -- your PD-1 versus other PD-1s. And I know this -- you've got some historical perspective as well around that and how those have changed over time.

Terry J. Rosen
Arcus Biosciences, Inc. - Co-Founder, Chairman & CEO

Sure. So we don't think the anti-PD-1 is underperforming in any way. We think zimberelimab, looks just like KEYTRUDA, looks like the other anti-PD-1s and without spending a ton of time

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot